ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2023
Pharmacologically active herbal remedies against atherosclerosis, characterization and DoE based marker quantification by densitometry, and cell based assays on THP-1 cell lines.
Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis is a complex condition that develops at varying rates in multiple configurations and blood vessels. The primary cause of morbidity and mortality worldwide, particularly in the industrialized nations, continues to be atherosclerosis. Ayurveda, Siddha, and Unani systems of medicine, among other traditional medical systems, utilize polyherbal compositions. The treatment of atherosclerosis has been improved with a novel multibotanical combination. In this study, we sought to formulate, characterize, and standardize a polyherbal formulation based on design of experiments (DoE), densitometric studies and to predict for antioxidant activity using molecular docking analysis based on LC- MS identified phytomarkers. In addition we have assessed its cell viability by MTT assay along with Ao/EtBr staining technique and intracellular ROS assay using THP-1 cell lines. Reported findings showed that the HPTLC based quantified components of selected multiherbals has the ability to treat for atherosclerosis. This document could be used to quickly authenticate the formulation as the method optimized was based on CCD design which shows desirability of 0.962 and 0.839. Cell based assays scientifically proves that the formulation was not toxic based on MTT assay along with AO/EtBr staining technique and has excellent antioxidant activities based on intracellular ROS assay using THP-1 cell lines. The observed findings would be crucial for future clinical aspects since the bioactive molecules contained in the extracts may have anticipated effects with other compounds and show a superior therapeutic potential. As a result, this study offers standardized and potentially therapeutic information about effective polyherbal formulation for atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.